Capricor Therapeutics (NASDAQ: CAPR) shares are trading higher on Tuesday after the company announced the U.S. Food and Drug Administration has accepted its investigational new drug application for a Phase 2 clinical trial of CAP-1002 in patients with COVID-19.The study will enroll patients who have a confirmed diagnosis of SARS-CoV-2 and require supplemental oxygen. CAPR Capricor Therapeutics $4.82 / -0.07 (-1.43%) 08/25/20 Capricor announces acceptance of IND application for Phase 2 trial of CAP-1002 05/13/20 Capricor Therapeutics announces top-line results from HOPE-2 study 04/29/20 Capricor: Data reports 100% survival in COVID-19 patients treated with CAP-1002 Investors need to know how sustainable this current run. Choosing to participate in a study is an important personal decision. Capricor Therapeutics Inc . Latest data shows the largest indicative borrow rate increases among liquid option names include: Frontline (FRO) 90.89% +79.75, Gogo (GOGO) 30.87% +1.23, Sundial Growers (SNDL) 44.05% +1.09, Capricor Therapeutics (CAPR) 32.97% +0.79, iBio (IBIO) 61.38% +0.78, Ballard Power (BLDP) 4.18% +0.64, Lemonade (LMND) 2.11% +0.29, AMC Entertainment (AMC) 66.56% +0.20, db X trackers China (ASHR) 7.35% +0.19, and SSR Mining (SSRM) 0.49% +0.15. CAP-1002 demonstrates immunomodulatory properties. PAPRs have become popular as they provide a level of comfort and protection that have sometimes been difficult to achieve with other respirators. Copyright © 2020. to treat up to 20 additional COVID-19 patients. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements. “We very much regret the difficulties the November cancellation will cause, and all our efforts are now directed to delivering a clinical exam in 2021. Elevation of at least 1 inflammatory biomarker (IL-1, IL-6, IL-10, TNF-a, ferritin, CRP) defined as ≥ 2x the upper limit of the laboratory, Written informed consent provided by the subject or legal representative, Male or female subjects at least 18 years of age at time of. Capricor Therapeutics to Present at The LD 500 Virtual Conference. It is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration. To add more color... Tellurian Inc. (NASDAQ:TELL) Recent Earnings Shows Major Promise, PepsiCo Inc. (NASDAQ:PEP) Stock is Soaring, Here is Why, The Rejuvenation of Stitch Fix Inc. (NASDAQ:SFIX), Renewed Optimism is Surrounding Simon Property Group Inc. (NYSE:SPG). For general information, Learn About Clinical Studies. IN DA MAKING !!!!!